Search

Rolling bearing is widely used in rotary machine; the unexpected failure affects the normal operation of the machine leads to production and financial losses to the industry. Hence, Rolling Element Bearing (REB) fault diagnosis is crucial. In this paper, raw bearing vibration signal is divided into the various intrinsic mode functions (IMFs) using Empirical Mode Decomposition (EMD). Statistical features are extracted from the first three IMFs of each conditions of the bearing. These features were given as inputs to K-NN classifier to classify different condition of the bearing.

PurposeRadiation therapy (RT) with doses ranging from 24 Gray (Gy) to 40 Gy is a proven treatment modality for indolent orbital adnexal lymphoma (IOAL), but recently the use of low dose RT (LDRT, defined as 2 Gy x 2 fractions) has become a notable alternative. However, limited data exists comparing outcomes following LDRT to moderate-dose RT (MDRT, RT dose 4 – 36 Gy). We present a single institution retrospective analysis comparing outcomes of patients with IOALs following LDRT or MDRT.MethodsA total of 36 patients treated with 38 consecutive courses of RT were identified; LDRT was delivered for 14 courses and MDRT for 24 courses. Overall response rates (ORR) were recorded according to Deauville or RECIST criteria with a response characterized as a complete response (CR) or partial response. Local control (LC), orbital control (OC), and overall survival (OS) rates were estimated with the Kaplan-Meier method. RT toxicity was graded per CTCAEv5 and compared with the Fisher’s exact test.ResultsMedian follow-up time was 29 months (m) (range, 4-129m), and median MDRT dose used was 24 Gy (range 21-36 Gy). Overall response rates (ORR) were 100% (CR 50%) and 87.5% (CR 58.3%) following LDRT and MDRT, respectively. OS at 2 years was 100% and 95% for the LDRT and MDRT groups, respectively (p=0.36). LC rates at 2 years was 100% for both LDRT and MDRT groups and at 4 years was 100% and 89% for the LDRT and MDRT groups, respectively (p=0.56). The 4-year OC rate (including both ipsilateral and contralateral relapses) was 80% and 85% for the LDRT and MDRT groups, respectively (p=0.79). No patient required treatment with RT to a previously irradiated orbit. Acute toxicities were reported following 6 LDRT courses compared to 20 MDRT courses (p=.014). No Grade 3 or higher acute toxicities occurred in either group. Late toxicities were reported following 2 LDRT courses compared to 10 MDRT courses (p=0.147).ConclusionsLDRT produced similar ORR, LC, OC, and OS rates compared to MDRT with fewer acute and minimal late toxicities reported. Future multi-center studies with larger patient numbers are warranted to show significant associations.

Purpose: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cells (CART-BCMA) are a promising treatment for relapsed/refractory multiple myeloma (r/rMM). We evaluated the safety and feasibility of bridging radiation (RT) in subjects treated on a phase I trial of CART-BCMA. Experimental Design: Twenty-five r/rMM subjects were treated in three cohorts with two doses of CART-BCMA cells ± cyclophosphamide. We retrospectively analyzed toxicity, response, and CART manufacturing data based on RT receipt. Results: Thirteen subjects received no RT Conclusions: Bridging-RT appeared safe and feasible with CART-BCMA therapy in our r/rMM patients, though larger future studies are needed to draw definitive conclusions.

Rubber seed oil (RSO), derived from the seeds of Hevea brasiliensis, is an exciting alternative with great potential for use in biodiesel production. Furthermore, it can be injected directly into an internal combustion engine, blended with diesel derived from fossil fuels. The present work deals with the potential estimation of waste cooking oil (WCO) bio diesel and RSO biodiesel, characterization of biodiesel, performance and exhaust analysis of biodiesel blends in DI diesel engine. The best results in terms of performance and emission are obtained for B10 blend which resulted in highest brake thermal efficiency of 19.2 % at 80% loading. The NOx emissions are maximum for B20 blend.

Purpose: Metastatic, persistent, or recurrent epithelial ovarian cancer (MPR-EOC) remains a significant threat to patient mortality despite advances in novel targeted agents. Radiation therapy (RT) is often used as a palliative option. We report outcomes of a large series of MPR-EOC patients treated with modern palliative RT (PRT) in an era of novel systemic therapies. Methods and Materials: A retrospective review was conducted of women treated with PRT for MPR-EOC between 2007 and 2019 at an academic institution. Clinical response rates were recorded at 3 months. Radiographic responses were categorized by RECIST 1.1 criteria. Overall response rate (ORR) was the sum of complete and partial response. Linear regression analyses of baseline characteristics were conducted for statistical testing. Results: Eighty-six patients with PMR-OC received 120 courses of palliative RT. Median follow-up was 8.6 months. Median age was 61 (range, 22-82). Thirty-six percent of women received central nervous system (CNS)-directed RT. In addition, 43% received targeted therapies before RT. Clinical ORR within 1 month and at last follow-up for non-CNS lesions was 79% and 61% (69% and 88% for CNS lesions, respectively). High-grade serous lesions were more likely to have clinical response (P = .04). Biologically effective doses (BED) >39 Gy were associated with improved clinical response in CNS lesions (P = .049). Bony sites were associated with worse clinical (P = .004) response in non-CNS lesions compared with soft tissue or nodal sites. Acute or late grade 3+ toxicities with bevacizumab were low (8.7%/4.3%). Conclusions: PRT offers excellent rates of response for symptomatic patients with MPR-EOC within 1 month of treatment, with durable responses beyond 3 months. High-grade serous lesions were associated with improved response in all patients. Higher BED and soft tissue or nodal sites were associated with improved response in CNS and non-CNS patients, respectively. Acute or late toxicities with bevacizumab and PRT were low. Prospective investigation is warranted to determine the optimal PRT regimen.

PURPOSE/OBJECTIVE(S) Most patients (pts) with relapsed/refractory (RR) cHL undergo salvage chemotherapy (CT) followed by curative-intent autologous stem cell transplant (ASCT). For failure post-ASCT, allogeneic stem cell transplant is considered in select cases. Given the morbidity of transplants, it is beneficial to assess if RT-based regimens can offer potential cure in RR cHL with less toxicity and without consolidative transplant. MATERIALS/METHODS We reviewed medical records of RR cHL pts salvaged between 2009 and 2019 with either RT alone or in combination with systemic therapy (ST) for 2nd line therapy and beyond (i.e., post-ASCT). We defined relapse as recurrence after complete response (CR) and refractory as failure to achieve CR after frontline/salvage therapy. Response and toxicity were assessed by Lugano criteria and CTCAEv.5, respectively. Kaplan Meier survival and univariate Cox regression analyses were performed. RESULTS We identified 26 pts (10 in RT vs. 16 in RT + ST) of which 88% had localized disease prior to RT-based salvage. All relapsed pts (n = 12) had localized relapse (stage I/II), and 50% had relapse > 1 yr after finishing frontline therapy. Relapsed pts who received frontline RT (n = 2) failed outside of prior fields. Reasons to forgo 2nd line therapy of ST followed by ASCT (n = 13) were localized disease/pt preference (92%) and comorbidities (8%). Most relapsed (67%) and refractory (64%) pts got RT + ST with 81% receiving brentuximab vedotin and 19% receiving pembrolizumab. Five pts received cytotoxic CT and then RT-based salvage, forgoing intended ASCT primarily due to refractory disease. After RT-based salvage (median dose 36 Gy (30-45)), 85% of pts achieved CR (70% in RT vs. 94% RT + ST) and 15% had progressive disease (30% in RT vs. 6% in RT + ST). 86% of pts with CR remained disease-free at 5 yrs. With a median follow up of 4.9 yrs, 5 yr PFS and OS for the entire cohort was 72% (95% CI: 56-92) and 92% (95% CI: 82-100), respectively. No significant difference in PFS was found between relapsed vs. refractory disease (HR = 0.7; 95% CI: 0.2-2.9; P = 0.6) or RT vs. RT + ST (HR = 1.8, 95% CI: 0.4-7.1; P = 0.4). Failures (n = 8) were categorized as isolated locoregional (outside of RT field) (38%), isolated distant (25%), combined local/locoregional/distant (25%); and local/locoregional (13%). Three grade (G) 3 and 0 ≥G4 events were reported. G2-3 ST-related toxicities included cytopenias (n = 2, 13%) and neuropathy (5, 31%), resulting in discontinuation/dose-reduction in 5 pts and hospitalization in 1. G2 RT-related toxicities included radiation pneumonitis (2, 8%), dermatitis (6, 23%), esophagitis (9, 35%), and hypothyroidism (5, 19%). CONCLUSION In this retrospective study, most RR cHL pts with localized disease achieved CR after RT-based salvage with low toxicity and without consolidative transplant. With a 5 yr PFS of 72%, RT-based salvage regimens appear effective and well-tolerated options for select RR cHL pts.